Can you share specific a1c improvements with ozempic?

Yes. In adults with type 2 diabetes, weekly Ozempic (semaglutide) generally lowers A1C by about 0.8–1.7 percentage points after roughly 26–52 weeks, with more reduction at the higher dose and in patients with higher starting A1C. Roughly:

- 0.5 mg once weekly: often about 0.8–1.3 percentage point drop in A1C by 26–52 weeks.
- 1 mg once weekly: usually about 1.0–1.7 percentage points drop by the same timeframe.

A larger reduction is typically seen in people who start with a higher A1C (e.g., around 9% or above). In many trials, a substantial portion of patients reached A1C targets (often <7%), especially at the higher dose, though results vary by baseline A1C, concurrent therapies, and adherence.

Notes:
- These figures come from the SUSTAIN program (semaglutide trials) and are averages; individual responses vary.
- A1C reductions are usually accompanied by weight loss (several kilograms over months) and cardio-vascular benefits in certain patients.
- Ozempic is approved for adults with type 2 diabetes to improve glycemic control, not for type 1 diabetes or obesity at these doses.

If you share your baseline A1C, the dose you’re considering (0.5 mg vs 1 mg weekly), and roughly how long you’ve been on treatment, I can give a more tailored approximation. Also, it’s best to discuss with your clinician to align with your specific treatment plan.